| Document Date: 2014-12-10 10:11:38
Open Document File Size: 164,17 KBShare Result on Facebook
Company MSD International Holdings GmbH / Merck Canada / / Country United States / Canada / / / Event FDA Phase / / Facility Maisonneuve Rosemont Hospital / / IndustryTerm animal health products / 5pipeline products / healthcare legislation / manufacturing difficulties / healthcare cost containment / health solutions / pharmaceutical industry regulation / healthcare / treatment of invasive aspergillosis in patients with disease / therapy for graft versus host disease / / MedicalCondition invasive aspergillosis / disease refractory / significant neutropenia / headache / myelodysplastic syndromes / graft-versus-host disease / host disease / neutropenia / nausea / Candida infections / fever / mucositis / vomiting / fewer breakthrough infections / aspergillosis / diarrhea / Invasive fungal infections / hypokalemia / acute myelogenous leukemia / / MedicalTreatment biologic therapies / immunosuppressive therapy / antifungal therapy / chemotherapy / / Organization Maisonneuve Rosemont Hospital / Securities and Exchange Commission / / Person Mauricio Ede / Michel Laverdière / Justin Holko / Annick Robinson / / / Position Infectious Disease Specialist / Executive Director / general economic factors / Director / Medical Affairs / Private / global healthcare leader / / Product POSANOL Oral Suspension / SOLUTION FOR INJECTION / itraconazole / POSANOL Delayed-Release Tablets / amphotericin B / POSANOL DelayedRelease Tablets / Oral Suspension / fluconazole / Delayed-Release Tablets / POSANOL® (posaconazole) Solution / POSANOL (posaconazole) Solution / POSANOL oral / Canada / for / POSANOL / / ProvinceOrState Quebec / / Technology chemotherapy / / URL www.sec.gov / www.merck.ca / /
SocialTag |
News Release ____________________________________________________________________________________ Media Contact: Investor Contact: